Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term b. Found 3 abstracts

Russo IH, Russo J, Deluca G, Janssens JP. hCG therapy for the treatment of breast cancer. 2000 Dec 15;:61 pp.
Tumang JR, Owyang A, Andjelic S, Jin Z, Hardy RR, Liou ML, Liou HC. c-Rel is essential for B lymphocyte survival and cell cycle progression. European Journal of Immunology. 1998 Dec;28(12):4299-312.
Zeng XX, Zhang HG, Hardy RR, Wasserman R. The fetal origin of B-precursor leukemia in the E mu-ret mouse. Blood. 1998 Nov 15;92(10):3529-36.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term b

b expression except adverse) Estrogens Role: BAC (Biological activity or effector-BSU (Biological study-unclassified)-THU (Therapeutic use)-BIOL (Biological study)-USES (Uses) (antiestrogens BSU (Biological study Gonadotropin receptors Role: BPR (Biological process)-unclassified)-BIOL (Biological study)-PROC (Process) (ligand gene rearrangements joining mechanism inhibitors Mammary gland (carcinoma pharmaceutical compn hCG breast cancer treatment Menopause (postmenopause cd40 NF-kappa B rel junctional sequences Antitumor agents (mammary gland carcinoma hCG breast cancer treatment nf-kappa-b transcription factors inhibitors Mammary gland (neoplasm-metastasis hCG therapy for treatment of breast cancer in premenopausal and postmenopausal women) apoptosis or a binding activity toward the hCG receptor for treatment of breast cancer) Drug delivery systems (compns contg hCG for treatment of breast cancer) transferase-positive cells receptor mice lacking hCG therapy for treatment of breast cancer) Antitumor agents (mammary gland pro- acute lymphoblastic-leukemia protein having the biol activity of hCG and proliferation immunoglobulin heavy-chain targeted disruption except adverse) Fusion proteins Role: BAC (Biological activity or effector-BSU (Biological study-unclassified)-THU (Therapeutic use)-BIOL (Biological study)-USES (Uses) (of LH-FSH-or TSH hCG therapy in combination with an antiestrogen or a Type I interferon for treatment of breast cancer) family inhibitors Mammary gland (metastasis clonal evolution metastasis Antitumor agents (mammary gland Mammary gland bone-marrow human t-lymphocytes except adverse) Interferons Role: BAC (Biological activity or effector-BSU (Biological study-unclassified)-THU (Therapeutic use)-BIOL (Biological study)-USES (Uses) (a Drug interactions (hCG therapy in combination with an antiestrogen or a Type I interferon for treatment of breast cancer) induced apoptosis inhibitors Mammary gland (neoplasm
Last updated on Tuesday, July 03, 2018